Skip to main content

Table 1 Characteristics of the patients (n = 20)

From: Pharmacokinetics and dose adjustment of etoposide administered in a medium-dose etoposide, cyclophosphamide and total body irradiation regimen before allogeneic hematopoietic stem cell transplantation

  

Mean ± S.D.

Median

Range

Age (year)

 

31.8 ± 7.0

31

18 – 44

Sex (male/female)

15/5

   

Body Weight (kg)

 

67.0 ± 12.5

65.0

45.5 – 91.8

Body surface area (m2)

 

1.8 ± 0.2

1.8

1.4 – 2.1

Body mass index (kg/m2)

 

23.2 ± 3.3

23.1

15.5 – 28.8

Diagnosis

    

  ALL

17

   

  AML

2

   

  ANKL

1

   

Disease status at SCT

    

  CR1

14

   

  CR2

1

   

  non CR

4

   

  relapse 1

1

   

Donor

    

  MRD

6

   

  MUD

7

   

  MMRD

1

   

  MMUD

6

   

Stem cell source

    

  Bone marrow

15

   

  Peripheral blood stem cells

3

   

  Umbilical cord blood

2

   

GVHD Prophylaxis

    

  CSP + MTX

9

   

  TAC + MTX

11

   

Laboratory data

    

  Alb (g/dL)

 

4.0 ± 0.4

4.0

2.8 – 4.9

  T-pro (g/dL)

 

6.0 ± 0.4

5.8

5.4 – 7.0

  BUN (mg/dL)

 

10.3 ± 3.0

10.5

5.0 – 15.0

  Scr (mg/dL)

 

0.6 ± 0.2

0.6

0.3 – 1.0

  T-bil (mg/dL)

 

0.7 ± 0.3

0.7

0.4 – 1.7

  AST (IU/L)

 

35.0 ± 31.4

21.0

9.0 – 125

  ALT (IU/L)

 

45.6 ± 54.6

32.0

5.0 – 251

  1. ALL indicates acute lymphoblastic leukemia, AML acute myelogenous leukemia, ANKL aggressive NK cell leukemia, SCT stem cell transplantation, CR complete remission, MRD HLA–matched related donor, MUD HLA-matched unrelated donor, MMRD mismatched related donor, MMUD mismatched unrelated donor, CSP cyclosporin A, MTX methotrexate, TAC tacrolimus, Alb albumin, T-pro total protein, BUN blood urea nitrogen, Scr serum creatinine, T-bil total bilirubin, AST asparatate aminotransferase, ALT alanine aminotransferase
Back to article page

Journal of Pharmaceutical Health Care and Sciences

ISSN: 2055-0294

Contact us